Plasma DNA, Microsatellite Alterations, and p53 Tumor Mutations Are Associated with Disease-Free Survival in Radically Resected Non-small Cell Lung Cancer Patients: A Study of the Perugia Multidisciplinary Team for Thoracic Oncology

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Thoracic Oncology

• Publication date

  2008-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/JTO.0b013e318168c7d0PMID 18379354
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The 2004 World Health Organization classification of lung tumors.

  2005cited by this paper
• The clinical relevance of Bcl-2, Rb and p53 expression in advanced non-small cell lung cancer.

  2003cited by this paper
• Real-Time Quantitative PCR

  2002cited by this paper
• The new World Health Organization classification of lung tumours

  2001cited by this paper
• Loss of heterozygosity is related to p53 mutations and smoking in lung cancer

  2001cited by this paper
• Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients.

  2001cited by this paper
• Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types

  1998cited by this paper
• Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer.

  1998cited by this paper
• Microsatellite instability and loss of heterozygosity at chromosomes 9 and 17 in non-small cell lung cancer.

  1998cited by this paper
• Chromosome 3p14 alterations in lung cancer: evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos.

  1998cited by this paper
• Homozygous deletions at 3p12 in breast and lung cancer

  1998cited by this paper
• Non-small cell lung cancer: clinical value of new biological predictors.

  1997cited by this paper
• Reduced survival in patients with stage‐I non‐small‐cell lung cancer associated with DNA‐replication errors

  1997cited by this paper
• Non-small cell lung cancer: clinical value of new biological predictors

  1997cited by this paper
• Prognostic value of replication errors on chromosomes 2p and 3p in non-small-cell lung cancer.

  1997cited by this paper
• Revisions in the International System for Staging Lung Cancer.

  1997cited by this paper
• Microsatellite alterations at 5q21, 11p13, and 11p15.5 do not predict survival in non-small cell lung cancer.

  1997cited by this paper
• Molecular damage in the bronchial epithelium of current and former smokers.

  1997cited by this paper
• Real time quantitative PCR.

  1996cited by this paper
• Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication.

  1996cited by this paper
• Fractional allele loss data indicate distinct genetic populations in the development of non-small-cell lung cancer.

  1996cited by this paper
• Comparative allelotype of early and advanced stage non‐small cell lung carcinomas

  1996cited by this paper
• Frequency and prognostic evaluation of 3p21‐22 allelic losses in non‐small‐cell lung cancer

  1995cited by this paper
• Loss of heterozygosity frequently affects chromosome 17q in non-small cell lung cancer.

  1995cited by this paper
• Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma.

  1995cited by this paper
• Sequential molecular genetic changes in lung cancer development.

  1995cited by this paper
• Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma.

  1995cited by this paper
• A food-borne outbreak of expensive antibiotic use in a community teaching hospital.

  1995cited by this paper
• Microsatellite instability and K-ras mutations associated with pancreatic adenocarcinoma and pancreatitis.

  1995cited by this paper
• Correlation of loss of heterozygosity at 11 p with tumour progression and survival in non‐small cell lung cancer

  1994cited by this paper
• Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer.

  1993cited by this paper
• Clues to the pathogenesis of familial colorectal cancer.

  1993cited by this paper
• Cooperation between oncogenes.

  1991cited by this paper
• Detection of specific polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of Thermus aquaticus DNA polymerase.

  1991cited by this paper
• A genetic model for colorectal tumorigenesis.

  1990cited by this paper
• Neoplastic characteristics of the DNA found in the plasma of cancer patients.

  1989cited by this paper
• Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease

  1983cited by this paper
• Quantitation and characterization of plasma DNA in normals and patients with systemic lupus erythematosus.

  1980cited by this paper
• Free DNA in the serum of cancer patients and the effect of therapy.

  1977cited by this paper
• The clonal evolution of tumor cell populations.

  1976cited by this paper
• Free DNA in serum and plasma from normal adults.

  1975cited by this paper

• Modulation of Peripheral Immune Cells Following Vitamin D3 Supplementation in Vitamin D-Insufficient Cancer Patients

  2025cites this paper
• Acetylation halts missense mutant p53 aggregation and rescues tumor suppression in non-small cell lung cancers

  2023cites this paper
• Maternal, neonatal, pregnancy outcome characteristics of pregnant women with high plasma cell-free DNA concentration in non-invasive prenatal screening: a retrospective analysis

  2023cites this paper
• A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer

  2023cites this paper
• Effect of Thoracic Epidural Anesthesia on Perioperative Neutrophil Extracellular Trapping Markers in Patients Undergoing Anesthesia and Surgery for Colorectal Cancer: A Randomized, Controlled Trial

  2023cites this paper
• Prognosis of recurrence after complete resection in early-stage lung adenocarcinoma based on molecular alterations: a systematic review and meta-analysis

  2023cites this paper
• Monitoring Somatic Genetic Alterations in Circulating Cell-Free DNA/RNA of Patients with “Oncogene-Addicted” Advanced Lung Adenocarcinoma: A Real-World Clinical Study

  2022cites this paper
• Tumor regionalization after surgery: Roles of the tumor microenvironment and neutrophil extracellular traps

  2022cites this paper
• Lung Adenocarcinoma: Next Generation Sequencing and Outcome in Regional Community Oncology Setting

  2021cites this paper
• The Role of Liquid Biopsy in Early Diagnosis of Lung Cancer

  2021cites this paper
• The role of extracellular DNA (exDNA) in cellular processes

  2021cites this paper
• Liquid Biopsy Biomarkers for Immunotherapy in Non-Small Cell Lung Carcinoma: Lessons Learned and the Road Ahead

  2021cites this paper
• Tumorspheres as an in vitro model for cancer stem-like cell characterization in non-small cell lung cancer. Prognostic implications

  2020cites this paper
• ERCC1 and XRCC1 single nucleotide polymorphisms can guide treatment decision in patients with metastatic non-small cell lung cancer

  2020cites this paper
• The prognostic impact of TP53 comutation in EGFR mutant lung cancer patients: a systematic review and meta-analysis

  2019cites this paper
• Progress in quantitative technique of circulating cell free DNA and its role in cancer diagnosis and prognosis.

  2019cites this paper
• Lung Cancer and Liquid Biopsy: Realities and Challenges in Routine Clinical Practice.

  2019cites this paper
• Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review.

  2019cites this paper
• Lung Cancer and Liquid Biopsy: Realities and Challenges in Routine Clinical Practice

  2019cites this paper
• Complete and Durable Response to Combined Chemo/Radiation Therapy in EGFR Wild-Type Lung Adenocarcinoma with Diffuse Brain Metastases

  2019cites this paper
• The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis

  2019cites this paper
• Early detection of lung cancer biomarkers through biosensor technology: A review

  2019cites this paper
• Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis.

  2018cites this paper
• A quantitative analysis of the potential biomarkers of non-small cell lung cancer by circulating cell-free DNA

  2018cites this paper
• Genetic Biomarkers and Their Applications to Prevent Occupational Diseases: A Literature Review

  2018cites this paper
• Cell-free DNA in non-small cell lung cancer

  2017cites this paper
• Plasma cell-free DNA and survival in non-small-cell lung cancer: A meta-analysis

  2017cites this paper
• Current methods of extracellular DNA methylation analysis

  2017cites this paper
• Quantitative Analysis of Circulating Cell‐Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta‐Analysis

  2017cites this paper
• Lung Cancer Biomarkers in Circulation

  2017cites this paper
• Quantification of Plasma Cell-Free Circulating DNA at Different Stages of Colorectal Cancer

  2017cites this paper
• Plasma cell-free DNA levels and integrity in patients with chest radiological findings: NSCLC versus benign lung nodules.

  2016cites this paper
• TP53 mutation is associated with a poor clinical outcome for non-small cell lung cancer: Evidence from a meta-analysis

  2016cites this paper
• Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer

  2016cites this paper
• New panel of microsatellite alterations detectable in the EBC for lung cancer prognosis

  2016cites this paper
• A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers.

  2016cites this paper
• Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win?

  2016cites this paper
• The diagnostic value of circulating cell free DNA quantification in non-small cell lung cancer: A systematic review with meta-analysis.

  2016cites this paper
• Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease

  2015influential citation
• Circulating DNA and Survival in Solid Tumors

  2015cites this paper
• [Generation of blood circulating DNA: the sources, peculiarities of circulation and structure].

  2015cites this paper
• Quantification of concentration and assessment of EGFR mutation in circulating DNA

  2015cites this paper
• Role of circulating-tumor DNA analysis in non-small cell lung cancer.

  2015cites this paper
• [Generation of blood circulating DNA: the sources, peculiarities of circulation and structure].

  2015cites this paper
• Extracellular Nucleic Acids and Cancer

  2015cites this paper
• Generation of blood circulating DNAs: Sources, features of struction and circulation

  2014cites this paper
• Association between smoking and p53 mutation in lung cancer: a meta-analysis.

  2014cites this paper
• Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer

  2014cites this paper
• Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients.

  2014cites this paper
• Assessment, origin, and implementation of breath volatile cancer markers.

  2014cites this paper
• The role of genetic and other biomarkers in NSCLC prognosis

  2014cites this paper
• Circulating cell-free DNA: a potential biomarker in lung cancer

  2013cites this paper
• Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

  2013cites this paper
• Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers.

  2013cites this paper
• Multiple Marker Detection in Peripheral Blood for NSCLC Diagnosis

  2013cites this paper
• Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer

  2013cites this paper
• Circulating DNA-Important Biomarker of Cancer

  2012cites this paper
• Can plasma DNA monitoring be employed in personalized chemotherapy for patients with advanced lung cancer?

  2012cites this paper
• Volatile organic compounds of lung cancer and possible biochemical pathways.

  2012cites this paper
• Quantitative analysis of free-circulating DNA in plasma of patients with resectable NSCLC

  2012cites this paper
• Association of p53 Arg72Pro polymorphism with gastric cancer: a meta-analysis

  2012cites this paper
• Increased levels of circulating DNA in patients with systemic autoimmune diseases: A possible marker of disease activity in Sjögren’s syndrome

  2011cites this paper
• Circulating Cell-Free DNA in Plasma of Never Smokers with Advanced Lung Adenocarcinoma Receiving Gefitinib or Standard Chemotherapy as First-Line Therapy

  2011cites this paper
• Introduction of hypoxia-targeting p53 fusion protein for the selective therapy of non-small cell lung cancer

  2011cites this paper
• Circulating DNA is a Useful Prognostic Factor in Patients with Advanced Non-small Cell Lung Cancer

  2011cites this paper
• Predictive Biomarkers and Personalized Medicine Circulating Cell-Free DNA in Plasma of Never Smokers with Advanced Lung Adenocarcinoma Receiving Gefitinib or Standard Chemotherapy as First-Line Therapy

  2011cites this paper
• Cell-free DNA in the blood as a solid tumor biomarker--a critical appraisal of the literature.

  2010cites this paper
• Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: a meta-analysis.

  2010cites this paper
• Circulating nucleic acids as a potential source for cancer biomarkers.

  2010cites this paper
• Clinical outcomes and correlates of TP53 mutations and cancer.

  2010cites this paper
• Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer.

  2010cites this paper
• Circulating DNA as a Biomarker for Early Detection of Cancer: A Brief Update with an Emphasis on Lung Cancer~!2010-06-09~!2010-08-03~!2010-09-06~!

  2010cites this paper
• From Expert Review of Molecular Diagnostics

  2010cites this paper
• Early detection and screening of lung cancer

  2010cites this paper
• Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN.

  2009cites this paper
• Le secretome, un modèle adapté à l'étude des protéines sécrétées par les tumeurs. Application à l'analyse du rôle joué par p53 sur la sécrétion de protéines par des cellules du cancer du poumon.

  2009cites this paper
• A review of novel biological tools used in screening for the early detection of lung cancer

  2009cites this paper
• Real-time PCR quantification of plasma DNA in non-small cell lung cancer patients and healthy controls

  2009cites this paper
• Free circulating nucleic acids in plasma and serum (CNAPS) -- Useful for the detection of lung cancer patients?

  2009cites this paper
• Lung cancer.

  2008cites this paper